株洲千金药业股份有限公司 2025年第三季度报告

Core Viewpoint - The company has announced significant changes in its governance structure, including the cancellation of the supervisory board and amendments to its articles of association, alongside updates on its financial performance and participation in national drug procurement programs [7][8][9][46]. Financial Performance - The company reported a 31.47% increase in revenue from the hygiene products segment compared to the same period last year, driven by rising demand for medical-grade sanitary napkins and increased promotional efforts [44]. - The company’s registered capital changed from RMB 42,399.7117 million to RMB 49,221.0016 million following the repurchase and cancellation of restricted stocks and the issuance of shares for asset acquisition [9][11]. Governance Changes - The supervisory board will be abolished, with its responsibilities transferred to the audit committee of the board of directors, in compliance with the revised Company Law and related regulations [8][9]. - Amendments to the articles of association include the removal of supervisory board provisions, updates on the responsibilities of the controlling shareholder, and the introduction of independent director sections [12][13][14]. Drug Procurement Participation - The company’s subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., has participated in the national drug procurement process, with three products expected to be selected for the 11th batch of national drug centralized procurement [46]. - The procurement cycle for selected products will run until December 31, 2028, which could enhance the company's market presence and brand influence if contracts are signed and executed successfully [51].